GlassScriptPhysician profile
Rhonda R Ray
NPI 1225685472
$10,203.99
in general payments reported to CMS, 2019-2025
19 companies · $2,379 in 2025
The $2,379 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,254 · 2022: $1,452 · 2023: $2,763 · 2024: $2,356 · 2025: $2,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,229 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,229.26 |
| Education | $268.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,958.54 | 2021-2025 | |
| Ucb, INC. | $2,101.56 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,118.25 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $811.69 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $662.86 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Pfizer INC. | $482.63 | 2021-2025 | |
| Lilly USA, LLC | $406.29 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $314.71 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $280.65 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $265.44 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $218.09 | 2025 | Nemluvio |
| Dermavant Sciences, INC. | $125.09 | 2023-2024 | Vtama |
| Incyte Corporation | $118.80 | 2023-2025 | Opzelura, Opzelura |
| Smith+Nephew, INC. | $74.79 | 2021-2023 | Grafix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.20 | 2023-2025 | Spevigo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $68.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.24 | 2022-2023 | |
| Leo Pharma INC. | $47.42 | 2024 | Adbry |
| Sandoz INC. | $19.39 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.